

BCCDC Certified Practice Decision Support Tool: Bacterial Vaginosis (BV)

The BCCDC decision support tools (DST) aim to provide more equitable, inclusive, and affirming care for all people, particularly for sexually diverse, transgender, Two-Spirit and non-binary people. While anatomy and site-specific testing language are used throughout this document, nurses should always strive to foster safer conversations and gender-affirming care by using an individual's chosen terminology when providing STI assessment and management.

Scope

Registered Nurses with **Reproductive Health – Sexually Transmitted Infection** Certified Practice designation [RN(C)] are authorized to manage, diagnose, and treat individuals with Bacterial Vaginosis.¹

Note: For individuals who are taking gender-affirming testosterone therapy or who have had gender-affirming vaginoplasty, and who have signs/symptoms of Bacterial Vaginosis, consult with and/or refer to a nurse practitioner (NP) or physician as additional tests and alternate treatment may be indicated.²⁻⁴ For more information please refer to the following:

- <u>Trans Care BC's Gender-affirming Care for Trans, Two-Spirit and Gender Diverse Patients in BC: A</u> <u>Primary Care Toolkit.</u>
- <u>BCCDC Certified Practice Assessment and Diagnostic Guideline: Sexually Transmitted Infections</u>

Etiology

Bacterial Vaginosis (BV) is a common imbalance of the vaginal flora caused by a depletion of lactobacilli and the presence and overgrowth of BV-associated bacteria⁵ (especially anaerobic, gram-negative bacilli) which may include:

- Gardnerella vaginalis
- Prevotella spp.
- Mobiluncus spp.
- Ureaplasma urealyticum
- Mycoplasma hominis

Epidemiology

BV is the most common cause of changes to normal vaginal discharge, affecting 23%–30% of reproductiveaged people⁶.

Risk Factors^{5, 7-11}

- Sexual contact with at least one partner
- New/multiple sexual partners
- Other STI (e.g., herpes simplex virus, chlamydia, gonorrhea)
- Intrauterine device (IUD)
- Cigarette smoking
- Douching

Clinical Presentation⁷⁻¹²

- Often asymptomatic
- Change in normal vaginal discharge
- Odour (fishy)
- Irritation

Physical Assessment¹²

- Individuals reporting signs and symptoms of BV should be offered a pelvic exam. Refer to the <u>BCCDC</u> <u>Certified Practice – Assessment and Diagnostic Guideline: Sexually Transmitted Infections.</u>
- Observation of reported changes in vaginal discharge which may include:
 - o Moderate to profuse amount
 - Homogenous (i.e., not clumpy)
 - o Greyish or white colour
 - o Thin
 - o Obvious BV (fishy) odour

Diagnostic and Screening Tests

Full STI screening is recommended. See <u>BCCDC Certified Practice – Assessment and Diagnostic Guideline:</u> <u>Sexually Transmitted Infections.</u>

Collect the following specimens from the vaginal wall (*may be obtained through clinician- or self-collected blind swab or by the clinician during a pelvic exam*):

- Swab for microscopy: smear on slide for gram stain
- Swab for pH
- Swab for KOH whiff test

Notes:

- Prepare glass slide for microscopy prior to using the sample for pH or KOH whiff test.
- pH strips are ineffective in the presence of blood.
- The KOH whiff test involves adding 10% KOH solution (not exceeding 0.5 ml) to collected vaginal secretions and briefly sniffing (1-2 seconds) the vapour to assess for an amine odour. Detection of an amine odour constitutes a positive whiff test. For more information on KOH whiff testing refer to the <u>Safe Use of 10% Potassium Hydroxide (KOH) in screening for STI.</u>

Management

Diagnosis and Clinical Evaluation


If signs or symptoms of BV are present, the following methods are available for BV diagnosis:

- Modified Amsel's Criteria
- Nugent scoring

Modified Amsel's Criteria: Clinical Management of Bacterial Vaginosis Symptoms in the Absence of Immediate Diagnostic Support

This method is useful for clinical management of BV when microscopic evaluation is not immediately available. Positive diagnosis is supported when the individual reports abnormal changes in vaginal discharge and at least two of the following are present:

- pH greater than (>) 4.5
- Presence of homogenous, moderate-profuse grey-white discharge
- Positive KOH whiff test OR obvious BV odour in the absence of the KOH whiff test



*Refer to Special Considerations & Consultation and Referral sections


**Refer to the Nugent Score: Laboratory-performed Gram Stain Microscopy algorithm

Nugent Score: Laboratory-performed Gram Stain Microscopy

Determined by lab with three possible scoring outcomes and interpretations⁷:

- Negative (0-3)
- Intermediate (4-6)
- Positive (7-10)

BCCDC Clinical Prevention Services Reproductive Health Decision Support Tool – Certified Practice Bacterial Vaginosis (BV) May 2025



*Refer to Special Considerations

Special considerations^{10, 12-15}

 Regardless of individual-reported symptoms, if clinical findings and/or lab-confirmed microscopy indicate positive or intermediate BV, treatment is recommended for those who are undergoing or have undergone upper genital tract instrumentation within the last 6 weeks. Examples include surgical abortion, dilation and curettage, or transvaginal hysterectomy. • Evidence suggests that IUD insertion is low risk for PID even in the presence of BV. Routine screening at time of IUD insertion is not recommended, and BV treatment at the time of or following IUD insertion is only indicated in the presence of symptoms.

Consultation and Referral

Consult with or refer to a physician or NP in the following situations:

- First choice and alternate treatment is contraindicated (see treatment guidance below)
- Pregnancy
- Breast/Chest feeding
- PID symptoms present
- Recurrent BV persistent symptoms after treatment of:
 - o 2 or more episodes of BV within a 4-week time frame
 - \circ 4 or more episodes of BV within a 1-year period

Treatment

Consult with or refer to a physician, NP or RN (c) (prescriber) for a prescription where appropriate

First ChoiceGeneral:Metronidazole 500 mg orally twice a day for 7 daysI. Though single dose metronidazole had treating BV (primarily due to recurre recommended when treatment comORClindamycin cream 2%, one applicator (5g) once a day intravaginally for 5 days ORI. Though single dose metronidazole had treating BV (primarily due to recurre recommended when treatment comORClindamycin cream 2%, one applicator (5g) intravaginally once a day for 7 daysI. Though single dose metronidazole 2 g orally in a single dose ORAlternate Metronidazole 2 g orally in a single dose ORGeneral:Indext (Clindamycin 300 mg orally twice a dayIndext (Clindamycin 300 mg orally twice a dayIndext (Clindamycin 300 mg orally twice a dayIndext (Clindamycin of alcohol is not contraindicate	
 for 7 days OR Metronidazole gel 0.75%, one applicator (5g) once a day intravaginally for 5 days OR Clindamycin cream 2%, one applicator (5g) intravaginally once a day for 7 days Alternate Metronidazole 2 g orally in a single dose OR Clindamusin 200 me avally twice a day 	
Clindamycin soo mg orany twice a day for 7 daysIngestion of alcohol is not contraindicate metronidazole therapy. Individuals may avoid alcohol and alcohol-containing meORavoid alcohol and alcohol-containing meClindamycin ovules 100 mg intravaginally once at bedtime for 3 daysNyquil®) for 12 hours prior to initiating to treatment, and for 24-48 hours after treatment.	hce), it may be oletion is a concern. A condoms and a. cid preparations as een conclusively bw promising results a used as adjunct htibiotics. ¹⁶⁻²⁰ Until mature to make a use. d during however, wish to dications (e.g., reatment, during

Monitoring and Follow-up

- Repeat testing: No
- Test-of-cure (TOC): No
- **Follow-up:** if symptoms resolve, follow-up is not required. If symptoms persist following initial treatment, ensure treatment compliance and re-evaluate to re-confirm diagnosis.

Partner Notification

- Reportable: No
- Trace-back period: N/A
- Recommended partner follow-up: Assessment and testing for BV should be offered to sexual partners
 with vaginal/vulvar anatomy (inclusive of vaginoplasty).²² For circumstances where treatment of
 partners with penile anatomy is being considered (e.g. monogamous couples where partner is
 agreeable to treatment to prevent BV recurrence) consult with NP or MD.²³

Potential Complications

- Presence of BV during an invasive procedure (e.g. surgical abortion, dilation & curettage), has been associated with post-procedure pelvic inflammatory disease (PID).^{13, 15}
- BV may be associated with premature rupture of membranes, preterm birth, intra-amniotic infection and post-partum endometritis.^{7, 24}

Additional Education

- Refraining from sexual activity or use condoms consistently during treatment.
- Vaginal flora and pH balance. Advise that certain practices such as intra-vaginal cleansing (douching) can alter vaginal flora and pH balance.
- Promising results in the investigation of available probiotic (lactobacillus or lactic acid formulations), antiseptics, and boric acid preparations for use in the treatment of BV; however, their exact efficacy as treatments for BV is unknown.
- IUD use associated with BV.
- The presence of BV can increase the likelihood of HIV transmission.
- The presence of BV can increase the likelihood of STI acquisition (e.g., HIV, GC, CT, HSV).
- If symptoms do not resolve with treatment, they will require referral to a physician or NP.
- BV may occur without having had sexual contact.
- Sexually Transmitted & Blood-Borne Infections: Standard Education

References

- British Columbia College of Nurses & Midwives (BCCNM). Section 8: Restricted activities for certified practice. [online]. 2024 [Accessed 6 November 2024]. Available from: https://www.basem.co/DN/(SecondPractice/part4/section8/Degas/Default.com/
 - https://www.bccnm.ca/RN/ScopePractice/part4/section8/Pages/Default.aspx
- Hallarn J, Bauer GR, Potter E, Wilcox H, Newfeld J, Krakowsky Y, Ravel J, Prodger JL. Gynecological concerns and vaginal practices and exposures among transfeminine individuals who have undergone vaginoplasty. The journal of sexual medicine. 2023 Nov;20(11):1344-52.
- 3. Thompson HM, Rusie LK, Schneider JA, Mehta SD. Bacterial vaginosis testing gaps for transmasculine patients may exacerbate health disparities. Frontiers in Reproductive Health. 2024 Feb 20;6:1344111.
- TransCare BC. Gender-affirming care for trans, two-spirit, and gender diverse patients in BC: a primary care toolkit. [online]. 2023 [Accessed 31 October 2024]. Available from: <u>https://www.transcarebc.ca/sites/default/files/2024-03/Primary-Care-Toolkit.pdf</u>
- 5. Morsli M, Gimenez E, Magnan C, Salipante F, Huberlant S, Letouzey V, Lavigne JP. The association between lifestyle factors and the composition of the vaginal microbiota: a review. European Journal of Clinical Microbiology & Infectious Diseases. 2024 Oct;43(10):1869-81.
- 6. Braunstein M, Selk A. Bacterial vaginosis. CMAJ. 2024 Jun 3;196(21):E728-.
- Centers for Disease Control and Prevention. Sexually transmitted infections treatment guidelines: bacterial vaginosis. [online]. 2021 [Accessed 7 November]. Available from: <u>https://www.cdc.gov/std/treatment-guidelines/bv.htm</u>
- Alberta Health Services. The bluebook standards for the management and evaluation of STI clinic clients. [online]. 2022 [Accessed 31 October 2024]. Available from: <u>https://www.albertahealthservices.ca/assets/info/hp/srh/if-hp-srh-the-blue-book.pdf</u>
- Australian STI Management Guidelines for Use in Primary Care. Bacterial Vaginosis. [online]. 2024 [Accessed 31 October 31 2024]. Available from: <u>https://sti.guidelines.org.au/sexually-transmissible-infections/bacterial-vaginosis/</u>
- 10. BASHH British Association for Sexual Health and HIV. Bacterial Vaginosis. [online]. 2012 [Accessed 31 October 2024]. Available from: <u>https://www.bashh.org/resources/21/bacterial_vaginosis_2012</u>
- 11. Government of Canada Canadian Guidelines on Sexually Transmitted Infections. STI associated syndromes guide: vaginitis. [online]. 2023 [Accessed 31 October 2024]. Available from: <u>https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/sti-associated-syndromes/vaginitis.html</u>
- 12. Up To Date. Bacterial vaginosis: clinical manifestations and diagnosis. [online]. 2024 [Accessed 31 October 2024]. Available from: <u>https://www.uptodate.com/contents/bacterial-vaginosis-clinical-manifestations-and-</u>

<u>diagnosis?search=bacterial%20vaginosis&source=search_result&selectedTitle=3%7E94&usage_type=d</u> <u>efault&display_rank=2</u>

- Caddy S, Yudin MH, Hakim J, Money DM, Allen VM, Bouchard C, Boucher M, Castillo E, Murphy KE, Ogilvie G, Paquet C. Best practices to minimize risk of infection with intrauterine device insertion. Journal of Obstetrics and Gynaecology Canada. 2014 Mar 1;36(3):266-74.
- 14. Alice TN, Kives S, Merovitz L, Nitsch R, Tessler K, Yudin MH. Screening for bacterial vaginosis at the time of intrauterine contraceptive device insertion: is there a role? Journal of Obstetrics and Gynaecology Canada. 2012 Feb 1;34(2):179-85.
- 15. Ziogou A, Ziogos E, Giannakodimos I, Giannakodimos A, Sifakis S, Ioannou P, Tsiodras S. Bacterial vaginosis and post-operative pelvic infections. InHealthcare 2023 Apr 25 (Vol. 11, No. 9, p. 1218). MDPI
- 16. Abavisani M, Sahebi S, Dadgar F, Peikfalak F, Keikha M. The role of probiotics as adjunct treatment in the prevention and management of gynecological infections: An updated meta-analysis of 35 RCT studies. Taiwanese Journal of Obstetrics and Gynecology. 2024 May 1;63(3):357-68.
- 17. Mittelstaedt R, Kretz A, Levine M, Handa VL, Ghanem KG, Sobel JD, Powell A, Tuddenham S. Data on safety of intravaginal boric acid use in pregnant and nonpregnant women: a narrative review. Sexually transmitted diseases. 2021 Dec 1;48(12):e241-7.
- 18. Soley L, Peterson A, Mott T. The role of pre/probiotics in the treatment of bacterial vaginosis. Evidence-Based Practice. 2023 Nov 1;26(11):2.
- 19. Wallace M, Rincon P, Burke D, Bovet C. Is boric acid effective at treating bacterial vaginosis?. Evidence-Based Practice.:10-97.
- 20. Sobel J. Achieving Effective Probiotic Therapy in Bacterial Vaginosis—Still an Unanswered Priority?. Sexually Transmitted Diseases. 2024 Jun 1;51(6):441-3.
- 21. Mergenhagen KA, Wattengel BA, Skelly MK, Clark CM, Russo TA. Fact versus fiction: a review of the evidence behind alcohol and antibiotic interactions. Antimicrobial agents and chemotherapy. 2020 Feb 21;64(3):10-128.
- 22. Vodstrcil LA, Bradshaw CS. Does Partner Treatment Impact on Bacterial Vaginosis Cure?. Clinical Infectious Diseases. 2021 Aug 1;73(3):e680-2.
- 23. Melbourne Sexual Health Centre. Clinician instructions for BV partner treatment. 2025. Available from: <u>https://www.mshc.org.au/images/general/LandingPage/PT4BV/ClinicianInstructions_BV.pdf</u>
- 24. Klebanoff MA, Schuit E, Lamont RF, Larsson PG, Odendaal HJ, Ugwumadu A, Kiss H, Petricevic L, Andrews WW, Hoffman MK, Shennan A. Antibiotic treatment of bacterial vaginosis to prevent preterm delivery: Systematic review and individual participant data meta-analysis. Paediatric and perinatal epidemiology. 2023 Mar;37(3):239-51.